Pharmafile Logo
Pharmafocus logo
Advanced Search

Biogen

Showing 15 posts of 117 posts found.

Biogen image

Biogen’s natalizumab fails Phase III endpoints

October 21, 2015
Biogen, multiple sclerosis

Biogen’s natalizumab has failed to achieve clinical endpoints in a late-stage study to prove the drug’s potential in patients with …

News
WHO flag

Novartis and Biogen launch drug access programmes in developing countries

October 15, 2015
Manufacturing and Production, Sales and Marketing Biogen, Novartis, access, aid, corporate social responsibility, csr, humanitarian aid

Novartis and Biogen have begun new campaigns aimed at increasing access to medicines in developing countries.  The Swiss firm has …

News
Alzheimer's research

Neurimmune kicks off late-stage Alzheimer’s study

September 9, 2015
Research and Development Alzheimer's disease, Biogen, Neurimmune, aducanumab, neurology

Neurimmune and its development partner Biogen are beginning a Phase III study of the companies’ potential Alzheimer’s treatment aducanumab.  The …

News
alzheimers_brain

Lilly, Biogen and Roche debut Alzheimer’s disease drug results

July 22, 2015
Research and Development Alzheimer's, Alzheimer's disease, Biogen, Conference, Eli Lilly, Roche, lilly

Big pharma companies have posted mixed results in trials of several potential new treatments for Alzheimer’s disease. But the results, …

News

Biogen to build billion-dollar plant in Switzerland

July 7, 2015
Manufacturing and Production Alzherimer's disease, Biogen, Biogen IDEC, MS, Switzerland, manufacturing, multiple sclerosis

Biogen plans to open a $1 billion manufacturing facility in Switzerland, to help Europe deal with the future demand for …

News
Google image

J&J and Google partner to build surgical robots

March 30, 2015
Medical Communications, Sales and Marketing Biogen, Ethicon, J&J, JJ, Johnson and Johnson, MS, google, robots

The medical device subsidiary of Johnson & Johnson Ethicon is to collaborate with Google to build surgical robots and perform …

News
Genome image

Big pharma teams with government on genomic research

March 27, 2015
Research and Development, Sales and Marketing AbbVie, Alexion Pharmaceuticals, AstraZeneca, Biogen, Cameron, Dimension Therapeutics, GSK, Genomic, Genomics england, Helomics, Roche, Takeda, UCB, UK, genomes

Ten firms will partner up with Genomics England to develop new diagnostics and treatments for people with rare diseases and …

News
Biogen image

Biogen shortens name and posts positive Alzheimer’s results

March 23, 2015
Sales and Marketing AD, Alzheimer's, BIIB037, Biogen, MS, Parkinson's, aducanumab, idec

Biogen Idec is to be known only as Biogen hence forth as the US biotech also reveals positive early results …

News
Google image

Google partners with Biogen on multiple sclerosis

January 30, 2015
Medical Communications, Sales and Marketing Biogen, MS, calico, conrad, google, google x, scangos

Google is making further headway into healthcare by teaming up with Biogen Idec in order to study what leads to …

News
Biogen image

EMA review for Biogen Idec’s haemophilia A therapy

November 4, 2014
Sales and Marketing Biogen, elocta, eloctate, haemophilia a, idec, sobi

The EMA is set to review Biogen Idec and Sobi’s haemophilia A therapy Elocta after validating the drug’s marketing authorisation …

News
Biogen Idec logo

NICE final ‘yes’ for Biogen’s MS pill

August 27, 2014
Sales and Marketing Aubagio, Biogen, RMS, RRMS, gilenya

In final guidance published today NICE has recommended NHS funding of Biogen Idec’s new multiple sclerosis pill in patients with …

News
Biogen image

FDA approves Biogen’s long-acting MS drug

August 18, 2014
Sales and Marketing Avonex, Biogen, FDA, MS, Rebif, plegridy, tecfidera

Biogen Idec has racked up another approval over the weekend after its latest multiple sclerosis treatment Plegridy gained FDA backing. …

News
biogen_austria_238

Biogen gets CHMP thumbs up

May 27, 2014
Sales and Marketing Biogen, CHMP, Gazyvaro (obinutuzumab), Nuwiq, Octapharma, Orphan, Roche, chronic lymphocytic leukaemia, plegridy

Biogen Idec is celebrating after the Committee for Medicinal Products for Human Use (CHMP) gave its multiple sclerosis drug Plegridy …

News
screen_shot_2014-01-29_at_10

High-dose Copaxone the right medicine for Teva

January 29, 2014
Research and Development, Sales and Marketing Biogen, Copaxone, FDA, MS, Mylan, Teva

The FDA has approved a high-dose version of Teva’s multiple sclerosis drug Copaxone which will help the firm offset approaching …

News
FDA image

US nod for Tecfidera

March 28, 2013
Sales and Marketing Biogen, FDA, tecfidera

The FDA has given Biogen Idec’s oral multiple sclerosis treatment Tecfidera the green light. Earlier this week Tecfidera (dimethyl fumarate) …

News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026